Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
Not yet recruiting · NCT07157514 · Registry updated 2025-09-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute leukemia, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Not yet recruiting | Phase 2 / Phase 3 | 2025-09-10 | NCT07157514 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Actinium Pharmaceuticals | 4 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||